Pfizer's 3 Points of Failure

Pfizer (NYSE: PFE  ) is not having a good March. Last week, its Cinderella story, Alzheimer's drug Dimebon, which it licensed from Medivation (Nasdaq: MDVN  ) , failed its first phase 3 trial for effectiveness. And then yesterday, the clinical-trial (March) madness continued with three more failures.

After failing a previous phase 3 trial, figitumumab was a No. 16 seed coming into the trial. Still, upsets are always possible ... it's anyone's game at this level ... and you can insert your own sports metaphor here.

Pfizer was testing figitumumab in combination with Roche and OSI Pharmaceuticals' (Nasdaq: OSIP  ) Tarceva for lung cancer, but a Data Safety Monitoring Committee recommended stopping the trial after an interim peek at the data showed that figitumumab plus Tarceva wasn't likely to extend survival longer than Tarceva alone.

Pfizer's Sutent, on the other hand, has made it to the Elite Eight. The drug is already approved to treat both kidney and gastrointestinal cancer and has been shown to work on pancreatic cancer as well. Expanding into breast cancer would have added substantial sales to the nearly $1 billion it brought in last year, but it wasn't meant to be. Pfizer announced that it was stopping two trials yesterday: one testing Sutent in combination with sanofi-aventis' (NYSE: SNY  ) Taxotere, and another testing it with Roche's Xeloda.

Sutent had failed a couple of trials for breast cancer, but those were head-to-head trials against current therapies: Xeloda in one trial and Roche's Avastin plus Bristol-Myers Squibb's (NYSE: BMY  ) Taxol in another. Pfizer's backup plan -- if you can't beat them, join them -- seemed sound, but like so many other drugs, Sutent doesn't seem to work in breast cancer.

Fortunately, Pfizer has a large pipeline; with the addition of Wyeth, its 34 (now 31) phase 3 programs could fill out half a bracket all on its own. The loss of a few programs won't kill Pfizer, but it sure would be nice to see it sink a few baskets soon.

By comparison, Pfizer's March has nothing on the tech bubble burst.

Pfizer is a recommendation of the Inside Value newsletter. If you're interested in picking through the wreckage for possible turnaround candidates, you should have the Inside Value team on your side. Check it out for free with a 30-day trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1134555, ~/Articles/ArticleHandler.aspx, 8/27/2014 11:42:45 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement